drugset / Trial / NCT00854581
Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma
Non-randomizedSequentialOpen-labelTreatment
Summary
RATIONALE: Human T-cell lymphotropic virus type 1 (HTLV-1) can cause cancer. Zidovudine is an antiviral drug that acts against the human T-cell lymphotropic virus type 1. Giving zidovudine, interferon alfa-2b, and PEG-interferon alfa-2b together may stimulate the immune system and slow down or keep the cancer cell from growing. PURPOSE: This clinical trial is studying how well giving zidovudine together with interferon alfa-2b and PEG-interferon alfa-2b works in treating patients with human T-cell lymphotropic virus type 1-associated adult T-cell leukemia/lymphoma.
Timeline
- Start
- 2007-11
- Primary completion
- 2011-06
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 1.5 ug/kg | Subcutaneous |
| Subject | Valproic Acid | Small molecule | 250 mg | Oral |
| Subject | Zidovudine | Small molecule | 300 mg | Intravenous |
| Subject | Zidovudine | Small molecule | 600 mg | Intravenous |
| Subject | interferon alfa-2b | Protein / enzyme biologic | 5e+06 iu | Intravenous |
| Subject | interferon alfa-2b | Protein / enzyme biologic | 1e+07 iu | Intravenous |